MBB core facilities and the SciLifeLab infrastructure contribute to the REMEDi4ALL project that kicks off with the ambition of establishing a European research and innovation eco-system facilitating fast and cost-effective patient-centric development and access to repurposed medicines.
MBB infrastructure scientists in CBCS, Chemical Proteomics and CRISPR Functional Genomics constituting the SciLifeLab platform for Chemical Biology and Genome Engineering (CBGE), will provide expertise in the development and use of in-silico and in-vitro driven drug repurposing and the realization of workflows for detailed drug mechanism of action understanding.
The team that will be involved from MBB are: Bernhard Schmierer, Massimiliano Gaetani, Annika Jenmalm Jensen, Brinton Seashore-Ludlow and Anna-Lena Gustavsson.
The project involves 24 European organisations and will receive 23M Euros from Horizon Europe over the next 5 years. KI recieves ca 18 MSEK of which MBB receives 13 MSEK over the next 5 years.
This article was first published on 29 September by Karolinska Institutet.
Receive our Policy Bulletin each Tuesday & Thursday and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
